Lapietra Gianfranco, Ferretti Antonietta, Baldacci Erminia, Chistolini Antonio, Santoro Cristina
Division of Hematology Department of Translational and Precision Medicine Policlinico Umberto I, Sapienza University of Rome Rome Italy.
EJHaem. 2022 Mar 9;3(2):453-456. doi: 10.1002/jha2.406. eCollection 2022 May.
Over the last 2 years, different cases of immune thrombocytopenia (ITP) in patients affected by SARS-CoV2 have been reported. The management of SARS-CoV2 in subjects with simultaneous or previous ITP can be challenging because of the great involvement of the haemostatic system in this viral infection. In this report, we describe the management and outcome of patients with newly diagnosed (ND), chronic and previous ITP, infected by COVID-19, referred to the Haematology Institute of University Hospital Policlinico Umberto I in Rome. Steroids + immunoglobulins for ND or relapsed ITP and continuation of home therapy for chronic ITP are advised, although further knowledge is required.
在过去两年中,已有关于感染严重急性呼吸综合征冠状病毒2(SARS-CoV2)的患者出现不同免疫性血小板减少症(ITP)病例的报道。对于同时患有或既往有ITP的患者,由于止血系统在这种病毒感染中受到极大影响,SARS-CoV2的管理可能具有挑战性。在本报告中,我们描述了罗马翁贝托一世大学医院血液学研究所收治的新冠病毒病(COVID-19)感染的新诊断(ND)、慢性和既往ITP患者的管理及转归。建议对新诊断或复发的ITP采用类固醇+免疫球蛋白治疗,对慢性ITP继续进行家庭治疗,不过仍需要更多了解。